THE ROLE OF INTRAVITREAL BEVACIZUMAB ON CYSTOID MACULAR EDEMA
Volume 11 , Issue 2 , June 2021 , Pages 189-194
Authors
Bakhtiar Qadir Hamasalh 1 ; Tablo Ahmed Mirza 2 ; Fazil Ahmad Abdulla 3
1 Department of Surgery, Ophthalmology College of Medicine, University of Sulaimani, Kurdistan Region, Iraq.
2 Shaheed Dr. Aso Teaching Eye Hospital, Kurdistan Region, Iraq.
3 Department of Community Medicine, College of Medicine, University of Sulaimani Kurdistan Region, Iraq.
10.17656/Jsmc.10302
Keywords
Abstract
Background
Cystoid macular edema (CME) is an intracellular accumulation of fluid in the retinal layers around the fovea; it contributes to reducing visual acuity by altering the functional cell relationship in the retina.
Objectives
To detect the role of intravitreal Bevacizumab (Avastin) on decreasing central retinal thickness in patients with cystoid macular edema.
Materials and Methods
In a prospective study in Shaheed Dr. Aso Eye Hospital in As-Suleimanyah city, 65 patients with macular edema by Ocular coherent tomography (OCT) included, after a single intravitreal avastin injection, we repeated the OCT after 2 weeks & 3 months after the injection.
Results
Central retinal thickness was greatly decreased in Diabetic patients and CRVO during the follow-up period, but a lesser effect was seen in BRVO. The immediate response was seen in ARMD after 2 weeks. Central retinal thickness decreased more in those patients who received Avastin alone than patients treated by Avastin with Laser photocoagulation. There was no significant improvement of visual acuity in the patients after IVTA injection
Conclusion
Avastin is an effective drug in decreasing central retinal thickness and delaying its complications mostly in patients with Diabetic retinopathy and CRVO, and reduces the need for LASER therapy in these patients.
Statistics
- Article view677
- Downloads3
- Published at21 June 2021
- RIS
- BibTeX
- EndNote
- Mendeley
- APA (7th edition)
- MLA (9th edition)
- Chicago
- Harvard
- IEEE
- Vancouver